PAREXEL International Corporation, the world’s leading innovator of
biopharmaceutical services, announced today that several of its experts
will discuss key issues facing the industry at the 54th Drug
Information Association (DIA) Annual Meeting, held from June 24 to 28,
2018 in Boston.
During the meeting, PAREXEL and the Economist Intelligence Unit (EIU)
will unveil new research findings in an independently produced report on
the impact of drug development innovations. The research findings will
be presented by Alberto Grignolo, Ph.D., Corporate Vice President of
PAREXEL and David Humphreys, Head of Health Policy Practice for the EIU
on Monday, June 25 at 1:30 p.m. E.T. in Innovation Theater 1.
In addition, PAREXEL will lead several formal presentations on key
Technology in Drug Development
Global Biopharmaceutical Climate
Real-World Data & Evidence
For more information about PAREXEL visit booth 1914 during the meeting
To schedule a briefing with a PAREXEL subject matter expert at DIA 2018,
Information about the DIA 2018 can be found at www.diahome.org.
About PAREXEL International
PAREXEL International Corporation is the world’s leading innovator of
biopharmaceutical services. We simplify our clients’ journey of
transforming scientific discoveries into new medical treatments for
patients with high-quality Phase I-IV clinical research, regulatory,
consulting and market access services. PAREXEL develops breakthrough
innovations and solutions by leveraging its comprehensive therapeutic,
technical and functional expertise, in more than 100 countries around
the world. For more information, visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks
of PAREXEL International Corporation or its affiliates. All other
trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180618005542/en/